This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Videos and case studies: ZAVICEFTA® in clinical practice

Listen to a selection of short videos where UK and international experts share their views on the role of ZAVICEFTA (ceftazidime-avibactam), share their clinical experience through patient cases in cUTI, cIAI or HAP/VAP, and in general about the challenges and management of Gram-negative infections.

Dr Matthew Dryden

Dr Matthew Dryden, Consultant Microbiologist at Hampshire Hospitals, discusses the REPRISE study.

Matteo Bassetti

Matteo Bassetti, Infectious Disease Specialist at Clinic University of Genova, Italy, presents a snapshot into the clinical usage of ZAVICEFTA to treat CRE and discusses key real-world evidence that supports ZAVICEFTA as a reasonable alternative to standard therapy in the management of infections due to KPC and OXA-48 producers.  

Alex Soriano

Alex Soriano, Infectious Disease Physician at Hospital Clinic in Barcelona, Spain summarises key ZAVICEFTA data against other β-lactam/β-lactamase inhibitor combinations. He discusses ZAVICEFTA’s in vitro activity and broad-spectrum coverage against MDR P. aeruginosa and Enterobacteriaceae (including Klebsiella pneumoniae, Escherichia coli and ESBL-producing strains). 

David Livermore

David Livermore, Professor of Medical Microbiology of the University of East Anglia in Norwich, provides an in-depth look into one of the key differentiating features for ZAVICEFTA – its activity against carbapenemase. He describes the poor clinical outcomes associated with OXA-48 and the key data that show treatment outcomes with ZAVICEFTA.

Clóvis Arns da Cunha

Clóvis Arns da Cunha, Professor Infectious Disease in Curitiba, Brazil, discusses in vitro activity of ZAVICEFTA (ceftazidime–avibactam) against carbapenemase-resistant Enterobacteriaceae.

Professor Philippe Montravers

Professor Philippe Montravers , specialist in Anaesthesia and Critical Care Medicine, at Assistance Publique Hospitaux Paris, presents a summary of data on β-lactam/β-lactamase inhibitors.

Professor Francesco G. De Rosa, Professor Philip Montravers and Dr Paula Ramirez

Professor Francesco G. De Rosa (Prof. of Infectious Diseases, Italy), Professor Philip Montravers (Anaesthesia and Critical Care Medicine, France) and Dr Paula Ramirez (Critical Care Department, Spain) discuss high-risk patients and early treatment of patients with suspected MDR Gram-negative infections in their clinical practice, and their experience using ZAVICEFTA.

Dr Matthew Dryden

Consultant Microbiologist at Hampshire Hospitals, comments on ZAVICEFTA and its role in clinical practice.

Professor Antoni Torres

Professor Antoni Torres, Professor of Pulmonology and Respiratory Critical Care Medicine at University of Barcelona, Spain, talks about hospital-acquired pneumonia and ventilator-associated pneumonia, as well as the REPROVE study, a Phase III randomised clinical trial comparing ceftazidime-avibactam to meropenem.

​​​​​​​Explore more

Access other case studies & videos

  • KOL Videos- Gram-negative
  • KOL Videos - Clinical experience
  • Webinars (Live & On-demand)
View Support & Services


​​​​​​​cUTI, complicated urinary tract infection, cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; BL/BLI, β-lactam/β-lactamase inhibitors; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; OXA, oxacillinase; ESBL, extended-spectrum β-lactamase; AMR, Antimicrobial Resistance

Prescribing information

Zavicefta (ceftazidime and avibactam) 2g/0.5 g Powder for Concentrate for Solution for Infusion

Meronem® (meropenem triydrate) IV 1g

Meronem® (meropenem triydrate) IV 500mg

Tazocin® (piperacillin sodium, tazobactam sodium) 2g/0.25g Powder for Solution for Infusion

Tazocin® (piperacillin sodium, tazobactam sodium) 4g/0.5g Powder for Solution for Infusion

Tygacil (tigecycline) 50mg powder for solution for infusion​​​​​​​

Amikacin (amikacin sulfate) 500mg/2ml solution for injection
Legal Category: Prescription Only Medicine (POM)
NHS Price: 5 vial pack £60.00
Click here for the Summary of Product Characteristics 

Gentamicin (gentamicin sulfate) 40 mg/ml Injection
Legal Category: Prescription Only Medicine (POM)
NHS Price: 5 vial £20.00 
Click here for the Summary of Product Characteristics

Ciprofloxacin (ciprofloxacin lactate) 2 mg/ml Solution for Infusion
Legal Category: Prescription Only Medicine (POM)
NHS Price: 10 bag £200.00 
Click here for the Summary of Product Characteristics

Tobramycin (tobramycin)
Tobramycin 240mg/6ml solution for injection
Legal Category: Prescription Only Medicine (POM) 
Basic NHS Cost: 1 vial £19.20
Click here for the Summary of Product Characteristics

Tobramycin 80mg/2ml solution for injection 
Legal Category: Prescription Only Medicine (POM) 
Basic NHS Cost: 5 vial £20.80
​​​​​​​Click here for the Summary of Product Characteristics

PP-ZVA-GBR-0842. June 2021

Join us!

Follow the link to learn about out upcoming meetings and online webinars event - dates, location and agendas.

Register here

Access results of ZAVICEFTA Phase III clinical trials in adult patients with cUTI, cIAI or HAP/VAP

  • REPROVE Phase III trial (HAP/VAP)

  • RECLAIM Phase III trial (cIAI)

  • RECAPTURE Phase III trial (cUTI)​​​​​​​

  • REPRISE Phase III trial (cIAI and cUTI)

Learn more about the tolerability data of ZAVICEFTA from four Phase III clinical trials.

View safety profile

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020